CD24 genetic variants contribute to overall survival in patients with gastric cancer

Table 2 Characteristics of subjects included n (%)

	Cancer	Atrophy	Controls	P value
n	679	111	976
Gender
Male	487 (71.7)	66 (59.5)	578 (59.2)	< 0.0001
Female	192 (28.3)	45 (40.5)	398 (40.8)
Age (yr)	61.0 (54.0-70.0)	50.0 (47.0-57.0)	48.5 (44.0-55.0)	< 0.0001
≤ 55	204 (30.0)	76 (68.5)	756 (77.5)	< 0.0001
55-70	310 (45.7)	28 (25.2)	181 (18.5)
> 70	165 (24.3)	7 (6.3)	39 (4.0)
H. pylori
Positive	453 (67.8)	84 (75.7)	478 (49.7)	< 0.0001
Negative	215 (32.2)	27 (24.3)	483 (50.3)
Differentiation
Poor	437 (68.4)
Moderate to well	202 (31.6)
Pathologic type
Tubular adenocarcinoma	545 (82.2)
Signet ring cell	50 (7.5)
Other	68 (10.3)
TNM stage
I	97 (15.0)
II	227 (35.1)
III	224 (34.6)
IV	99 (15.3)
Distant metastasis
Positive	573 (85.3)
Negative	99 (14.7)
Post-operational Chemotherapy
No	456 (67.2)
FOLFOX-4	100 (14.7)
XELOX	47 (6.9)
Other	76 (11.2)

Data are presented as frequency counts (percentage of total) or median (25^th to 75^th percentiles).